{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:53:10Z","timestamp":1791168790940,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["HL081009"],"award-info":[{"award-number":["HL081009"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["5T32HL007411"],"award-info":[{"award-number":["5T32HL007411"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001145","name":"AHA","doi-asserted-by":"publisher","award":["14GRNT20460090"],"award-info":[{"award-number":["14GRNT20460090"]}],"id":[{"id":"10.13039\/501100001145","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.thromres.2015.05.027","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T02:34:42Z","timestamp":1432866882000},"page":"493-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease"],"prefix":"10.1016","volume":"136","author":[{"given":"Eitan A.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin L.","family":"Ogletree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias V.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Boutaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.thromres.2015.05.027_bb0005","doi-asserted-by":"crossref","first-page":"14847","DOI":"10.1016\/S0021-9258(18)33360-X","article-title":"Characterization of the biosynthetic pathway of prostaglandin D2 in human platelet-rich plasma","volume":"257","author":"Watanabe","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2015.05.027_bb0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-4615-9442-0_9","article-title":"Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets","volume":"192","author":"Whittle","year":"1985","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2008.01.001","article-title":"Thromboxane A2: physiology\/pathophysiology, cellular signal transduction and pharmacology","volume":"118","author":"Nakahata","year":"2008","journal-title":"Pharmacol. Ther."},{"issue":"19","key":"10.1016\/j.thromres.2015.05.027_bb0020","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/01.CIR.0000093194.21109.EC","article-title":"Thromboxane A2 regulates vascular tone via its inhibitory effect on the expression of inducible nitric oxide synthase","volume":"108","author":"Yamada","year":"2003","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.thromres.2015.05.027_bb0025","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1097\/01.ASN.0000136300.72480.86","article-title":"Thromboxane receptor mediates renal vasoconstriction and contributes to acute renal failure in endotoxemic mice","volume":"15","author":"Boffa","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.thromres.2015.05.027_bb0030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/01.RES.0000138300.41642.15","article-title":"Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration","volume":"95","author":"Ashton","year":"2004","journal-title":"Circ. Res."},{"issue":"11","key":"10.1016\/j.thromres.2015.05.027_bb0035","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJM198809153191106","article-title":"Clinical implications of prostaglandin and thromboxane A2 formation (1)","volume":"319","author":"Oates","year":"1988","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2015.05.027_bb0040","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1172\/JCI117510","article-title":"Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder","volume":"94","author":"Hirata","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2000-9802","article-title":"Pathogenesis of a bleeding disorder characterized by platelet unresponsiveness to thromboxane A2","volume":"26","author":"Fuse","year":"2000","journal-title":"Semin. Thromb. Hemost."},{"issue":"6","key":"10.1016\/j.thromres.2015.05.027_bb0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0049-3848(82)90311-5","article-title":"A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2","volume":"26","author":"Defreyn","year":"1982","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.1981.tb07194.x","article-title":"Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism","volume":"49","author":"Defreyn","year":"1981","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0060","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1172\/JCI113223","article-title":"Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism","volume":"80","author":"Gresele","year":"1987","journal-title":"J. Clin. Invest."},{"issue":"8229","key":"10.1016\/j.thromres.2015.05.027_bb0065","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0140-6736(81)92241-8","article-title":"Thromboxane synthetase inhibition as antithrombotic strategy","volume":"1","author":"Vermylen","year":"1981","journal-title":"Lancet"},{"issue":"1 Suppl.","key":"10.1016\/j.thromres.2015.05.027_bb0070","first-page":"I12","article-title":"Biosynthesis and pharmacological modulation of thromboxane in humans","volume":"81","author":"Patrono","year":"1990","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1527-3466.2001.tb00058.x","article-title":"Ifetroban sodium: an effective TxA2\/PGH2 receptor antagonist","volume":"19","author":"Rosenfeld","year":"2001","journal-title":"Cardiovasc. Drug Rev."},{"issue":"3","key":"10.1016\/j.thromres.2015.05.027_bb0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0014-2999(01)00904-9","article-title":"Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding","volume":"417","author":"Kawano","year":"2001","journal-title":"Eur. J. Pharmacol."},{"issue":"9782","key":"10.1016\/j.thromres.2015.05.027_bb0085","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)60600-4","article-title":"Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial","volume":"377","author":"Bousser","year":"2011","journal-title":"Lancet"},{"issue":"5567","key":"10.1016\/j.thromres.2015.05.027_bb0090","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.1068711","article-title":"Role of prostacyclin in the cardiovascular response to thromboxane A2","volume":"296","author":"Cheng","year":"2002","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.thromres.2015.05.027_bb0095","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2015.05.027_bb0100","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-015-3241-1","article-title":"Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review","author":"Garcia de la Pena Lefebvre","year":"2015","journal-title":"Rheumatol. Int."},{"issue":"11","key":"10.1016\/j.thromres.2015.05.027_bb0105","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1161\/CIRCULATIONAHA.106.174526","volume":"113","author":"Hirsch","year":"2006","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.thromres.2015.05.027_bb0110","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/ejvs.2000.1175","article-title":"Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group","volume":"20","year":"2000","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"4","key":"10.1016\/j.thromres.2015.05.027_bb0115","first-page":"229","article-title":"Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost","volume":"10","author":"Balzer","year":"1991","journal-title":"Int. Angiol."},{"issue":"20","key":"10.1016\/j.thromres.2015.05.027_bb0120","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-2008-1066673","article-title":"Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study","volume":"114","author":"Diehm","year":"1989","journal-title":"Dtsch. Med. Wochenschr."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0125","first-page":"64","article-title":"Short-term and long-term effects of one-week treatment with intravenous iloprost in critical limb ischemia patients (Leriche-Fontaine stage III and IV)","volume":"24","author":"Meini","year":"2005","journal-title":"Int. Angiol."},{"issue":"4","key":"10.1016\/j.thromres.2015.05.027_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM198407263110401","article-title":"The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men","volume":"311","author":"Hardy","year":"1984","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.thromres.2015.05.027_bb0135","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJM198609253151304","article-title":"Release of prostaglandin D2 into human airways during acute antigen challenge","volume":"315","author":"Murray","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"126","key":"10.1016\/j.thromres.2015.05.027_bb0140","doi-asserted-by":"crossref","first-page":"126ra34","DOI":"10.1126\/scitranslmed.3003122","article-title":"Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia","volume":"4","author":"Garza","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1084\/jem.193.2.255","article-title":"Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2","volume":"193","author":"Hirai","year":"2001","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.thromres.2015.05.027_bb0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Group","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0090-6980(88)90093-7","article-title":"The biology and pharmacology of PGD2","volume":"35","author":"Giles","year":"1988","journal-title":"Prostaglandins"},{"issue":"20","key":"10.1016\/j.thromres.2015.05.027_bb0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1021\/ja00332a049","article-title":"Solvent-induced fragmentation of prostaglandin endoperoxides. New aldehyde products from PGH2 and a novel intramolecular 1,2-hydride shift during endoperoxide fragmentation in aqueous solution","volume":"106","author":"Salomon","year":"1984","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.thromres.2015.05.027_bb0165","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1172\/JCI111509","article-title":"Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels","volume":"74","author":"Charo","year":"1984","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0170","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1172\/JCI111125","article-title":"Arachidonic acid and prostaglandin endoperoxide metabolism in isolated rabbit and coronary microvessels and isolated and cultivated coronary microvessel endothelial cells","volume":"72","author":"Gerritsen","year":"1983","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0175","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1096\/fj.03-0473com","article-title":"Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis","volume":"18","author":"Kuwano","year":"2004","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.thromres.2015.05.027_bb0180","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/HYPERTENSIONAHA.107.088948","article-title":"Prostaglandin E2 induces vascular relaxation by E-prostanoid 4 receptor-mediated activation of endothelial nitric oxide synthase","volume":"50","author":"Hristovska","year":"2007","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0185","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1476-5381.1994.tb16997.x","article-title":"Potent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery","volume":"113","author":"Qian","year":"1994","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0190","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11239-011-0577-6","article-title":"The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood","volume":"32","author":"Schober","year":"2011","journal-title":"J. Thromb. Thrombolysis"},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0195","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1084\/jem.20061617","article-title":"Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors","volume":"204","author":"Gross","year":"2007","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0200","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0741-5214(97)70210-6","article-title":"Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms","volume":"25","author":"Holmes","year":"1997","journal-title":"J. Vasc. Surg."},{"issue":"8","key":"10.1016\/j.thromres.2015.05.027_bb0205","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/hc3401.093152","article-title":"Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability","volume":"104","author":"Cipollone","year":"2001","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.thromres.2015.05.027_bb0210","first-page":"545P","article-title":"Formation and release of prostaglandins by platelets in response to thrombin","volume":"40","author":"Smith","year":"1970","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0215","first-page":"412","article-title":"Cyclic nucleotides and phosphodiesterases in platelets","volume":"82","author":"Haslam","year":"1999","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2015.05.027_bb0220","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0026-895X(25)09693-2","article-title":"Model of prostaglandin-regulated cyclic AMP metabolism in intact platelets: examination of time-dependent effects on adenylate cyclase and phosphodiesterase activities","volume":"36","author":"Ashby","year":"1989","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0225","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0026-895X(25)09417-9","article-title":"Novel mechanism of heterologous desensitization of adenylate cyclase: prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets","volume":"38","author":"Ashby","year":"1990","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.thromres.2015.05.027_bb0230","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0022-3565(25)12210-6","article-title":"Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation","volume":"275","author":"Vezza","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.thromres.2015.05.027_bb0235","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.RES.0000251742.71301.16","article-title":"Activation of platelet function through G protein-coupled receptors","volume":"99","author":"Offermanns","year":"2006","journal-title":"Circ. Res."},{"issue":"14","key":"10.1016\/j.thromres.2015.05.027_bb0240","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1073\/pnas.95.14.8070","article-title":"Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation","volume":"95","author":"Jin","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.thromres.2015.05.027_bb0245","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1055\/s-0037-1614384","article-title":"Role of intracellular signaling events in ADP-induced platelet aggregation","volume":"82","author":"Daniel","year":"1999","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2015.05.027_bb0250","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0022-3565(25)38928-7","article-title":"Separate receptors for prostacyclin and prostaglandin E2 on human gel-filtered platelets","volume":"236","author":"Eggerman","year":"1986","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0255","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1006\/bbrc.1993.2470","article-title":"Cloning and expression of the EP2 subtype of human receptors for prostaglandin E2","volume":"197","author":"An","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.thromres.2015.05.027_bb0260","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1006\/bbrc.1994.1142","article-title":"Cloning and expression of the EP3-subtype of human receptors for prostaglandin E2","volume":"198","author":"Yang","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0265","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0026-895X(25)09674-9","article-title":"Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype","volume":"46","author":"Regan","year":"1994","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0270","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0031-6997(25)06784-5","article-title":"International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes","volume":"46","author":"Coleman","year":"1994","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0275","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1046\/j.1365-2141.1998.00910.x","article-title":"Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells","volume":"102","author":"Paul","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0280","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.thromres.2010.04.003","article-title":"PGE2 decreases reactivity of human platelets by activating EP2 and EP4","volume":"126","author":"Smith","year":"2010","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0285","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pharmthera.2004.06.003","article-title":"Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation","volume":"103","author":"Hata","year":"2004","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0290","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/09537101003718065","article-title":"The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function","volume":"21","author":"Iyu","year":"2010","journal-title":"Platelets"},{"issue":"4","key":"10.1016\/j.thromres.2015.05.027_bb0295","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1160\/TH10-01-0043","article-title":"Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation","volume":"104","author":"Kuriyama","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2015.05.027_bb0300","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1210\/endo.141.4.7405","article-title":"The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs","volume":"141","author":"Suzawa","year":"2000","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0305","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1084\/jem.20021408","article-title":"Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth","volume":"197","author":"Amano","year":"2003","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.thromres.2015.05.027_bb0310","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/09537100802351073","article-title":"DG-041 inhibits the EP3 prostanoid receptor\u2013a new target for inhibition of platelet function in atherothrombotic disease","volume":"19","author":"Heptinstall","year":"2008","journal-title":"Platelets"},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0315","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3109\/09537104.2011.625575","article-title":"PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors","volume":"23","author":"Glenn","year":"2012","journal-title":"Platelets"},{"issue":"48","key":"10.1016\/j.thromres.2015.05.027_bb0320","doi-asserted-by":"crossref","first-page":"14496","DOI":"10.1021\/bi00252a016","article-title":"Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals","volume":"33","author":"An","year":"1994","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0325","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0026-895X(25)10545-2","article-title":"Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions","volume":"48","author":"Kotani","year":"1995","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0330","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1432-1033.1995.tb20223.x","article-title":"Splice variants of the human EP3 receptor for prostaglandin E2","volume":"228","author":"Schmid","year":"1995","journal-title":"Eur. J. Biochem."},{"issue":"10","key":"10.1016\/j.thromres.2015.05.027_bb0335","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1016\/S0021-9258(19)50448-3","article-title":"Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype","volume":"267","author":"Sugimoto","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0340","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1432-1033.1993.tb18248.x","article-title":"Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase","volume":"217","author":"Irie","year":"1993","journal-title":"Eur. J. Biochem."},{"issue":"6442","key":"10.1016\/j.thromres.2015.05.027_bb0345","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/365166a0","article-title":"Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity","volume":"365","author":"Namba","year":"1993","journal-title":"Nature"},{"issue":"48","key":"10.1016\/j.thromres.2015.05.027_bb0350","doi-asserted-by":"crossref","first-page":"46035","DOI":"10.1074\/jbc.M208519200","article-title":"Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors","volume":"277","author":"Yang","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.thromres.2015.05.027_bb0355","doi-asserted-by":"crossref","first-page":"9984","DOI":"10.1073\/pnas.180194597","article-title":"Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs","volume":"97","author":"Yang","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0360","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1476-5381.1993.tb12810.x","article-title":"Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues","volume":"108","author":"Matthews","year":"1993","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0365","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1172\/JCI10881","article-title":"Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation","volume":"107","author":"Fabre","year":"2001","journal-title":"J. Clin. Investig."},{"issue":"7","key":"10.1016\/j.thromres.2015.05.027_bb0370","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3109\/09537104.2011.576284","article-title":"P2Y(1)(2) and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP","volume":"22","author":"Iyu","year":"2011","journal-title":"Platelets"},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0375","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0090-6980(94)90084-1","article-title":"A novel inhibitory prostanoid receptor in piglet saphenous vein","volume":"47","author":"Coleman","year":"1994","journal-title":"Prostaglandins"},{"issue":"9","key":"10.1016\/j.thromres.2015.05.027_bb0380","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nrm1197","article-title":"Epac: a new cAMP target and new avenues in cAMP research","volume":"4","author":"Bos","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.thromres.2015.05.027_bb0385","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.cellsig.2008.08.007","article-title":"PGE(2) induces COX-2 expression in podocytes via the EP(4) receptor through a PKA-independent mechanism","volume":"20","author":"Faour","year":"2008","journal-title":"Cell. Signal."},{"issue":"4","key":"10.1016\/j.thromres.2015.05.027_bb0390","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1074\/jbc.M109440200","article-title":"Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2","volume":"277","author":"Fujino","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.thromres.2015.05.027_bb0395","doi-asserted-by":"crossref","first-page":"12151","DOI":"10.1074\/jbc.M212665200","article-title":"Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases","volume":"278","author":"Fujino","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0400","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1124\/mol.105.017749","article-title":"EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein","volume":"69","author":"Fujino","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.thromres.2015.05.027_bb0405","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.RES.0000204451.88147.96","article-title":"A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling","volume":"98","author":"Takayama","year":"2006","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.thromres.2015.05.027_bb0410","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1161\/ATVBAHA.110.216374","article-title":"The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation","volume":"30","author":"Philipose","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2\u20133","key":"10.1016\/j.thromres.2015.05.027_bb0415","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0014-5793(01)02640-0","article-title":"Agonist-induced internalization and mitogen-activated protein kinase activation of the human prostaglandin EP4 receptor","volume":"501","author":"Desai","year":"2001","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0420","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1073\/pnas.0510562103","article-title":"Role of beta-arrestin 1 in the metastatic progression of colorectal cancer","volume":"103","author":"Buchanan","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0425","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1074\/jbc.M110.118018","article-title":"Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets","volume":"286","author":"Li","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2015.05.027_bb0430","series-title":"Nobel Symposium 11. Prostaglandins","first-page":"241","article-title":"Influence of prostaglandins on platelet adhesiveness and platelet aggregation","author":"Kloeze","year":"1967"},{"issue":"63","key":"10.1016\/j.thromres.2015.05.027_bb0435","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/newbio236045a0","article-title":"Effect of prostaglandin E 2 and aspirin on the secondary aggregation of human platelets","volume":"236","author":"Shio","year":"1972","journal-title":"Nat. New Biol."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0440","first-page":"111","article-title":"Interaction of prostaglandins E1 and E2 in regulation of cyclic-AMP and aggregation in human platelets: evidence for a common prostaglandin receptor","volume":"84","author":"McDonald","year":"1974","journal-title":"J. Lab. Clin. Med."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0445","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0090-6980(80)90170-7","article-title":"On the multiplicity of platelet prostaglandin receptors. I. Evaluation of competitive antagonism by aggregometry","volume":"19","author":"Andersen","year":"1980","journal-title":"Prostaglandins"},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0450","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0014-2999(91)90124-9","article-title":"Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP","volume":"194","author":"Gray","year":"1991","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0455","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0014-2999(85)90620-X","article-title":"The effects of PGE2 and CL 115,347, an antihypertensive PGE2 analogue, on human blood platelet behaviour and vascular contractility","volume":"114","author":"Gray","year":"1985","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.thromres.2015.05.027_bb0460","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood.V82.9.2704.2704","article-title":"Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C","volume":"82","author":"Vezza","year":"1993","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0465","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2141.1976.tb00929.x","article-title":"Prostaglandin E2 potentiation of platelet aggregation induced by LASS endoperoxide: absent in storage pool disease, normal after aspirin ingestion","volume":"32","author":"Weiss","year":"1976","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2015.05.027_bb0470","first-page":"383","article-title":"Modulation of platelet activation by prostaglandin E2 mimics","volume":"21A","author":"Thierauch","year":"1991","journal-title":"Adv. Prostaglandin Thromboxane Leukot. Res."},{"key":"10.1016\/j.thromres.2015.05.027_bb0475","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0031-6989(69)80047-0","article-title":"Divergent effects of epinephrine and prostaglandin E1 on the level of cyclic AMP in human blood platelets","volume":"1","author":"Robison","year":"1969","journal-title":"Pharmacol. Res. Commun."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0480","first-page":"45","article-title":"Cyclic AMP turnover in response to prostaglandins in intact platelets: evidence for separate stimulatory and inhibitory prostaglandin receptors","volume":"12","author":"Ashby","year":"1988","journal-title":"Second Messengers Phosphoproteins"},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0485","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1388-1981(99)00164-X","article-title":"The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs","volume":"1483","author":"Abramovitz","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.thromres.2015.05.027_bb0490","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/hc3601.094003","article-title":"Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP(3)","volume":"104","author":"Ma","year":"2001","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.thromres.2015.05.027_bb0495","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI59262","article-title":"Niacin and biosynthesis of PGD(2)by platelet COX-1 in mice and humans","volume":"122","author":"Song","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.thromres.2015.05.027_bb0500","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/cvr\/cvt276","article-title":"Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence","volume":"101","author":"Tilly","year":"2014","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0505","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1021\/cb8002094","article-title":"Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding","volume":"4","author":"Singh","year":"2009","journal-title":"ACS Chem. Biol."},{"issue":"8","key":"10.1016\/j.thromres.2015.05.027_bb0510","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2007.06.005","article-title":"The evasive nature of drug efficacy: implications for drug discovery","volume":"28","author":"Galandrin","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104463","article-title":"Functional selectivity and classical concepts of quantitative pharmacology","volume":"320","author":"Urban","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.thromres.2015.05.027_bb0520","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/157015907781695973","article-title":"Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs","volume":"5","author":"Kenakin","year":"2007","journal-title":"Curr. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0525","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrd3024","article-title":"Teaching old receptors new tricks: biasing seven-transmembrane receptors","volume":"9","author":"Rajagopal","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0530","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1124\/jpet.109.156398","article-title":"Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands","volume":"331","author":"Leduc","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1\u20132","key":"10.1016\/j.thromres.2015.05.027_bb0535","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.prostaglandins.2010.11.001","article-title":"PGE1 and PGE2 modify platelet function through different prostanoid receptors","volume":"94","author":"Iyu","year":"2011","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.thromres.2015.05.027_bb0540","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1749-6632.1972.tb16287.x","article-title":"Cyclic 3',5'-adenosine monophosphate in human blood platelets. IV. Regulatory role of cyclic amp in platelet function","volume":"201","author":"Salzman","year":"1972","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0545","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-3565(25)21020-5","article-title":"Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders","volume":"246","author":"Gresele","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0550","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0049-3848(80)90387-4","article-title":"Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour","volume":"20","author":"Heptinstall","year":"1980","journal-title":"Thromb. Res."},{"issue":"8228","key":"10.1016\/j.thromres.2015.05.027_bb0555","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(81)92224-8","article-title":"Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation","volume":"1","author":"Bartele","year":"1981","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.thromres.2015.05.027_bb0560","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/0006-2952(84)90577-X","article-title":"Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2","volume":"33","author":"Gresele","year":"1984","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.thromres.2015.05.027_bb0565","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/01.CIR.72.6.1194","article-title":"The biochemical pharmacology of thromboxane synthase inhibition in man","volume":"72","author":"FitzGerald","year":"1985","journal-title":"Circulation"},{"issue":"5533","key":"10.1016\/j.thromres.2015.05.027_bb0570","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/258337a0","article-title":"Calcium-dependent stimulation of platelet aggregation by PGE","volume":"258","author":"MacIntyre","year":"1975","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.thromres.2015.05.027_bb0575","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.tips.2008.05.002","article-title":"Potentiation and priming of platelet activation: a potential target for antiplatelet therapy","volume":"29","author":"Gresele","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0580","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3109\/09537104.2012.704648","article-title":"Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers","volume":"24","author":"Fox","year":"2013","journal-title":"Platelets"},{"issue":"20","key":"10.1016\/j.thromres.2015.05.027_bb0590","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/01.CIR.0000128046.54681.97","article-title":"Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4","volume":"109","author":"Xiao","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0595","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/cvr\/cvn254","article-title":"Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia\/reperfusion injury","volume":"81","author":"Hishikari","year":"2009","journal-title":"Cardiovasc. Res."},{"issue":"8","key":"10.1016\/j.thromres.2015.05.027_bb0600","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/labinvest.2013.85","article-title":"Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6","volume":"93","author":"Mohamed","year":"2013","journal-title":"Lab. Investig."},{"issue":"17","key":"10.1016\/j.thromres.2015.05.027_bb0605","doi-asserted-by":"crossref","first-page":"11155","DOI":"10.1074\/jbc.M710038200","article-title":"Cyclooxygenase-2 up-regulates CCR7 via EP2\/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells","volume":"283","author":"Pan","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"28","key":"10.1016\/j.thromres.2015.05.027_bb0610","doi-asserted-by":"crossref","first-page":"29797","DOI":"10.1074\/jbc.M313989200","article-title":"Colon carcinoma cell growth is associated with prostaglandin E2\/EP4 receptor-evoked ERK activation","volume":"279","author":"Pozzi","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.thromres.2015.05.027_bb0615","doi-asserted-by":"crossref","first-page":"9665","DOI":"10.1158\/0008-5472.CAN-06-1271","article-title":"Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0620","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ibd.21080","article-title":"Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial","volume":"16","author":"Nakase","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"issue":"29","key":"10.1016\/j.thromres.2015.05.027_bb0625","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1200\/JCO.2009.22.3032","article-title":"Cancer, clots and consensus: new understanding of an old problem","volume":"27","author":"Lyman","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.thromres.2015.05.027_bb0630","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.thromres.2015.05.027_bb0635","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.thromres.2015.05.027_bb0640","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jcp.24539","article-title":"Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer","volume":"229","author":"Sharma","year":"2014","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0645","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12885-015-1304-z","article-title":"Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells","volume":"15","author":"Orellana","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.thromres.2015.05.027_bb0650","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/mol.113.084988","article-title":"Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells","volume":"84","author":"Dovizio","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.thromres.2015.05.027_bb0655","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues","volume":"94","author":"Thun","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.thromres.2015.05.027_bb0660","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/1535-7163.1031.3.8","article-title":"Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?","volume":"3","author":"Hull","year":"2004","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.thromres.2015.05.027_bb0665","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1158\/0008-5472.CAN-05-4348","article-title":"Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis","volume":"66","author":"Ma","year":"2006","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.thromres.2015.05.027_bb0670","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/carcin\/22.12.2001","article-title":"Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development","volume":"22","author":"Kawamori","year":"2001","journal-title":"Carcinogenesis"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384815300074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384815300074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:22:17Z","timestamp":1748406137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384815300074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":133,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0049384815300074"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2015.05.027","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2015.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}